Abstract:
:Microarrays for gene expression profiling are rapidly becoming important research tools for the identification of novel markers, for example, for novel classification of leukemias and lymphomas. Here, we review the considerations and infrastructure for microarray experiments. These considerations are illustrated via a microarray-based comparison of gene expression profiles of paired diagnosis-relapse samples from patients with precursor-B acute lymphoblastic leukemia (ALL), who relapsed during therapy or after completion of treatment. Initial experiments showed that several seemingly differentially expressed genes were actually derived from contaminating non-leukemic cells, particularly myeloid cells and T-lymphocytes. Therefore, we purified the ALL cells of the diagnosis and relapse samples if their frequency was lower than 95%. Furthermore, we observed in earlier studies that extra RNA amplification leads to skewing of particular gene transcripts. Sufficient (non-amplified) RNA of purified and paired diagnosis-relapse samples was obtained from only seven cases. The gene expression profiles were evaluated with Affymetrix U95A chips containing 12 600 human genes. These diagnosis-relapse comparisons revealed only a small number of genes (n=6) that differed significantly in expression: mostly signaling molecules and transcription factors involved in cell proliferation and cell survival were highly upregulated at relapse, but we did not observe any increase in drug-resistance markers. This finding fits with the observation that tumors with a high proliferation index have a poor prognosis. The genes that changed between diagnosis and relapse are currently not in use as diagnostic or disease progression markers, but represent potential new markers for such applications. Leukemia (2003) 17, 1324-1332. doi:10.1038/sj.leu.2402974
journal_name
Leukemiajournal_title
Leukemiaauthors
Staal FJ,van der Burg M,Wessels LF,Barendregt BH,Baert MR,van den Burg CM,van Huffel C,Langerak AW,van der Velden VH,Reinders MJ,van Dongen JJdoi
10.1038/sj.leu.2402974subject
Has Abstractpub_date
2003-07-01 00:00:00pages
1324-32issue
7eissn
0887-6924issn
1476-5551pii
2402974journal_volume
17pub_type
杂志文章相关文献
LEUKEMIA文献大全abstract::Human cytomegalovirus (CMV) infections and relapse of disease remain major problems after allogeneic stem cell transplantation (allo-SCT), in particular in combination with CMV-negative donors or cordblood transplantations. Recent data suggest a paradoxical association between CMV reactivation after allo-SCT and reduc...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2012.374
更新日期:2013-06-01 00:00:00
abstract::Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic respon...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400858
更新日期:1997-12-01 00:00:00
abstract::Mucosa-associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the nuclear factor (NF)-kappaB pathway. Gastric MALT lymphomas harboring such translocations usually do not respond to Helicobacter pyl...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2010.118
更新日期:2010-08-01 00:00:00
abstract::Primary myelofibrosis (PMF) is a hematopoietic stem cell (HSC) disease, characterized by aberrant differentiation of all myeloid lineages and profound disruption of the bone marrow niche. PMF samples carry several mutations, but their cell origin and hierarchy in regulating the different waves of clonal and aberrant m...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-018-0159-0
更新日期:2019-01-01 00:00:00
abstract::The choice of adequate controls for reverse transcriptase (RT-) PCR analysis has been the focus of a debate pursued in Leukemia over the past 3 years. Twenty-six authors from 15 different centers contributed to the Debate, and the points presented have been carefully evaluated. This survey reviews the issues discussed...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/sj.leu.2402133
更新日期:2001-07-01 00:00:00
abstract::Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring sideroblasts (RS). RS is a cardinal feature of refractory anemia with RS (RARS) and RARS with marked thrombocytosis (RARS/-T). Mutations in SF3B1, a member of ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2014.170
更新日期:2015-01-01 00:00:00
abstract::During the 15 year period 1975-1989, 74 cases of chronic myeloproliferative disorder (CMPD) were cytogenetically analyzed in our department. Thirty patients had polycythemia vera (PV), 23 had idiopathic myelofibrosis (MFS), 15 had idiopathic thrombocythemia (IT), and six had unclassifiable CMPD (UCMPD). The overall fr...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:
更新日期:1991-03-01 00:00:00
abstract::Osteolysis resulting in extensive bone damage is a major clinical manifestation of patients with multiple myeloma (MM). The mechanisms of bone resorption in MM are incompletely understood. The final pathway is the generation of activated osteoclasts within bone marrow (BM) microenvironment. To investigate the mechanis...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1995-08-01 00:00:00
abstract::We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfav...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2010.234
更新日期:2011-01-01 00:00:00
abstract::Cord blood (CB) is an attractive alternative to bone marrow or peripheral blood as a source of transplantable hematopoietic tissue. However, because of the reduced volume, the stem cell content is limited; therefore its use as a graft for adult patients might require ex vivo manipulations. Two systems have been descri...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401003
更新日期:1998-05-01 00:00:00
abstract::Therapy-related myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML) are serious complications of chemotherapy and radiotherapy for cancer. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be associated with an increased incidence of these complications. The frequency o...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402631
更新日期:2002-09-01 00:00:00
abstract::We report here the case of a 55-year-old patient with chronic granular lymphocyte disorder associated with moderate neutropenia. The majority of peripheral blood lymphocytes displayed a CD3-, CD8-, CD16+, CD56(NKH1)- phenotype. The patient's cells showed high spontaneous cytotoxic activity against K562 targets and dev...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1992-05-01 00:00:00
abstract::We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or l...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404653
更新日期:2007-06-01 00:00:00
abstract::Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-018-0334-3
更新日期:2019-06-01 00:00:00
abstract::The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2016.225
更新日期:2017-02-01 00:00:00
abstract::Methodology has been developed that enables virtually complete purification and recovery of early hematopoietic progenitors from human adult blood, a minority of which is multipotent and endowed with self-renewal capacities, i.e., exhibits stem cell properties. This report briefly reviews: (i) the key steps involved i...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1992-11-01 00:00:00
abstract::A novel erythroid cell line, RM10, was established from a long-term bone marrow culture of a patient with chronic myelogenous leukemia (CML). RM10 cells were positive for periodic acid Schiff (PAS), but negative for peroxidase and dual esterase. RM10 cells had la, pre B (CD10), myeloid (CD13, CD14, CD33) and erythroid...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1990-05-01 00:00:00
abstract::t(8;21)(q22;q22) is the most frequently observed karyotypic abnormality associated with acute myeloid leukemia (AML), especially in FAB M2. Clinically, this type of AML often shows eosinophilia and has a high complete remission rate with conventional chemotherapy. t(8;21) AML is also frequently associated with additio...
journal_title:Leukemia
pub_type: 杂志文章,多中心研究
doi:10.1038/sj.leu.2402871
更新日期:2003-04-01 00:00:00
abstract::This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...
journal_title:Leukemia
pub_type: 杂志文章,多中心研究
doi:10.1038/leu.2017.327
更新日期:2018-04-01 00:00:00
abstract::We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2405014
更新日期:2008-02-01 00:00:00
abstract::Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, rela...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:10.1038/sj.leu.2402599
更新日期:2002-09-01 00:00:00
abstract::The standard paradigm of embryologic development and adult tissue reconstitution posits unidirectional, hierarchical lineages. The presumed mechanisms underlying these differentiative pathways are gene restrictions, such as methylation and heterochromatin formation, which are commonly described as irreversible. Howeve...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/sj.leu.2402445
更新日期:2002-04-01 00:00:00
abstract::We have analyzed the expression of Tdt and CD7 in 335 cases of unequivocal acute myeloid leukemia (AML). Tdt was expressed in 80 (25%) of 321 evaluable cases. Twenty-six of 77 (34%) Tdt+ patients assessable for response, entered complete remission (CR) vs 121 of 209 (58%) Tdt- cases (P < 0.001). CD7 was expressed in 1...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401067
更新日期:1998-07-01 00:00:00
abstract::Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC locus and deregulation of upstream pathways such as IRF4, DIS3/LIN28B/...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-018-0036-x
更新日期:2018-06-01 00:00:00
abstract::Inhibitory proteins for Cdks (CKIs) are involved in cell cycle arrest induced by anti-mitotic factors, chemicals, or DNA damage in mammalian cells. High cell density also induces cell cycle arrest with unreplicated genomic DNA even in the presence of mitotic dose of the growth factors, termed contact inhibition. Altho...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::In this study, the abilities of constitutive and conditional forms of the three Raf kinases to abrogate the cytokine dependency of FDC-P1 cells were examined. The constitutively active forms (delta) of all three Raf kinases were fused to the hormone-binding domain of the estrogen receptor (ER), rendering their activit...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401720
更新日期:2000-04-01 00:00:00
abstract::The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 (n=231), TT2 (n=668) without or with thalidomide and TT3 with added bortezomib (n=303) have been reported. An...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2012.160
更新日期:2013-01-01 00:00:00
abstract::Response rates of 20% were achieved when interferon alpha (IFN) was applied as single agent treatment for multiple myeloma. A synergistic activity was observed when IFN was combined with chemotherapeutic agents in vitro and in vivo. These observations led to a series of randomized trials comparing chemotherapy alone w...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:
更新日期:1997-12-01 00:00:00
abstract::The expression of the myeloperoxidase (MPO) gene was studied, by means of Northern blot analysis in 14 cases of acute myeloid leukemia (AML), 11 cases of chronic myeloid leukemia (CML), and 6 cases of CML blast crisis, and in HL60 cells before and after induction of terminal differentiation with retinoic acid (RA), ph...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1989-06-01 00:00:00
abstract::APL-associated hemostasis disorders result from at least two distinct mechanisms due to the release of procoagulant activities and plasminogen activators from the leukemic cells. These two mechanisms (thrombin activation and plasmin activation) may cleave the fibrinogen molecule, but their respective roles in low fibr...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1995-01-01 00:00:00